Anavasi Diagnostics

Seattle, United States Founded: 2020 • Age: 6 yrs
Molecular detectors for COVID-19 detection are manufactured.
Request Access

About Anavasi Diagnostics

Anavasi Diagnostics is a company based in Seattle (United States) founded in 2020 by Minh Duong, Robert Atkinson, and Barry Lutz.. Anavasi Diagnostics has raised $6 million across 2 funding rounds from investors including NIH. Anavasi Diagnostics offers products and services including AscencioDx Molecular Detector and AscencioDx Covid-19 Test. Anavasi Diagnostics operates in a competitive market with competitors including Alveo Technologies, Luas Diagnostics, VIRIS Detection Systems, BioHermes and DxLab, among others.

  • Headquarter Seattle, United States
  • Founders Minh Duong, Robert Atkinson, Barry Lutz
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $6 M (USD)

    in 2 rounds

  • Latest Funding Round
    $14.9 M (USD), Grant

    Nov 10, 2021

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Anavasi Diagnostics

Anavasi Diagnostics offers a comprehensive portfolio of products and services, including AscencioDx Molecular Detector and AscencioDx Covid-19 Test. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Rapid portable tool for detecting SARS-CoV-2 in point-of-care settings.

Nucleic acid detection kit for SARS-CoV-2 variants in medical environments.

People of Anavasi Diagnostics
Headcount 10-50
Employee Profiles 7
Board Members and Advisors 2
Employee Profiles
People
Christine Campbell
Senior Project Manager
People
Barry Lutz
Co-Founder & Chief Scientific Officer
People
Debra Patterson
VP, Regulatory Affairs
People
George Stone
Director of Quality

Unlock access to complete

Funding Insights of Anavasi Diagnostics

Anavasi Diagnostics has successfully raised a total of $6M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $14.9 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Grant — $14.9M
  • First Round

    (10 Nov 2021)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2021 Amount Grant - Anavasi Diagnostics Valuation

investors

NIH
Nov, 2021 Amount Angel Round - Anavasi Diagnostics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Anavasi Diagnostics

Anavasi Diagnostics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include NIH. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Drug discovery services are provided to the biopharma sector.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Anavasi Diagnostics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Anavasi Diagnostics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Anavasi Diagnostics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Anavasi Diagnostics

Anavasi Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alveo Technologies, Luas Diagnostics, VIRIS Detection Systems, BioHermes and DxLab, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Cloud-powered POC MDx device
domain founded_year HQ Location
Sensors and connected app are developed for diabetes management.
domain founded_year HQ Location
CRISPR-based RNA-guided diagnostics for SARS-CoV-2 detection are developed.
domain founded_year HQ Location
Provider of POC diagnostic devices and kits
domain founded_year HQ Location
Point-of-care devices for infectious disease detection are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Anavasi Diagnostics

Frequently Asked Questions about Anavasi Diagnostics

When was Anavasi Diagnostics founded?

Anavasi Diagnostics was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Anavasi Diagnostics located?

Anavasi Diagnostics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.

Is Anavasi Diagnostics a funded company?

Anavasi Diagnostics is a funded company, having raised a total of $6M across 2 funding rounds to date. The company's 1st funding round was a Grant of $14.9M, raised on Nov 10, 2021.

What does Anavasi Diagnostics do?

Anavasi Diagnostics was established in 2020 in Seattle, United States. Operations are centered in the diagnostics sector, with molecular detectors for COVID-19 produced as the primary focus. The company is led by co-founders Minh Duong, Robert Atkinson, and Barry Lutz, who also serves as chief scientific officer. Development and manufacturing of these diagnostic tools occur within the biotechnology field, targeting infectious disease testing needs in the region.

Who are the top competitors of Anavasi Diagnostics?

Anavasi Diagnostics's top competitors include Alveo Technologies, DxLab and BioHermes.

What products or services does Anavasi Diagnostics offer?

Anavasi Diagnostics offers AscencioDx Molecular Detector and AscencioDx Covid-19 Test.

Who are Anavasi Diagnostics's investors?

Anavasi Diagnostics has 1 investor. Key investors include NIH.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available